ArticleCardiovascular diabetology2025
Longitudinal study reveals plasma glycans associations with prediabetes/type 2 diabetes in KORA study.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Large glycomics datasets as a tool to understand the function of glycans.Nature chemical biology · 2026Review
- Integrated glycoproteomics reveals site-specific N-glycosylation defects in phosphomannomutase two congenital disorder of glycosylation.The Journal of biological chemistry · 2026Article
- Artificial intelligence in prediabetes care: applications in screening, risk prediction, and lifestyle intervention.Frontiers in endocrinology · 2026Review
- Association between estimated glucose disposal rate and the risk of atherosclerotic cardiovascular disease: insight from cross-sectional and retrospective cohort studies.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAltered plasma N-glycosylation is increasingly recognized as a contributor to metabolic dysregulation. This study aimed to investigate the role of plasma N-glycans in glucose metabolism and the progression from normoglycemia to prediabetes and type 2 diabetes (T2D).
methodsWe analyzed longitudinal data from 473 participants in the Cooperative Health Research in the Region of Augsburg (KORA) cohort over 7 years. N-glycan profiles were measured using hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescence detection (HILIC-UHPLC-FLR). Glycan associations with incident prediabetes/T2D and related traits, such as body mass index (BMI), fasting glucose, homeostasis model assessment of insulin resistance (HOMA-IR) were evaluated using longitudinal models based on N-glycan measurements obtained at F4 and FF4. Classification performance at FF4 was assessed using machine learning models interpreted with SHapley Additive exPlanation (SHAP) values. Mendelian randomization (MR) and glycan quantitative trait loci (glycan-QTL) analyses were conducted to explore causality and genetic determinants.
resultsDuring follow-up, 231 individuals progressed to prediabetes/T2D, while 242 remained normoglycemic. Nineteen glycans were associated with diabetes progression in the basic model; 12 remained significant after full adjustment. Glycans such as GP18 and GP32 were also linked to metabolic traits. A glycan-clinical model achieved high classification accuracy (AUC = 0.895). MR supported causal roles for GP18, GP19, and S1. Glycan-QTL analysis revealed SNPs and genes (FUT8, ST3GAL4) are associated with key glycans.
conclusionsPlasma N-glycans are diagnostic of early glycemic deterioration and supported by genetic and causal evidence, highlighting their potential as biomarkers for diabetes risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.